ASH 2021 CAR-T In-depth

First-Line Axi-Cel Appears Effective in High-Risk Large B-Cell Lymphoma

At a median follow-up of 15.9 months, the median duration of response was not reached.

Smartphone App Helps Guide Use of CAR T-Cell, BiTE Therapy

The “myTcell” app is expected to be released in the United States in 2022.

Anakinra Can Prevent Severe CRS, ICANS After CAR T-Cell Therapy

There was 1 case of grade 3 CRS and 1 case of grade 4 CRS.

Reinfusion of CAR-T Cells May Prevent Relapse in Acute Lymphoblastic Leukemia

The findings of this study prompted a change in clinical practice.

Brexu-Cel Deemed Safe, Effective for Mantle Cell Lymphoma in Real-World Study

Outcomes were similar to those seen in the ZUMA-2 trial.

Hospitalization, ED Visits Highest in First Month After CAR T-Cell Infusion

Sixty-seven percent of rehospitalizations occurred within the first month of CAR T-cell infusion.